Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Neoadjuvant Therapy|Pathological Complete Response|Immunotherapy|Vinorelbine|Cisplatin
Interventions: DRUG: Camrelizumab with vinorelbine and cisplatin
Sponsor: Peking University First Hospital